#676 Dexcom G7 is Getting Close

May 5, 2022Scott Benner

Jake Leach Executive Vice President and Chief Technology Officer at Dexcom is back to talk G7.

You can always listen to the Juicebox Podcast here but the cool kids use: Apple Podcasts/iOS - Spotify - Amazon Music - Google Play/Android - iHeart Radio - Radio Public, Amazon Alexa or wherever they get audio.

+ Click for EPISODE TRANSCRIPT

DISCLAIMER: This text is the output of AI based transcribing from an audio recording. Although the transcription is largely accurate, in some cases it is incomplete or inaccurate due to inaudible passages or transcription errors and should not be treated as an authoritative record. Nothing that you read here constitutes advice medical or otherwise. Always consult with a healthcare professional before making changes to a healthcare plan.

Scott Benner 0:00
Hello friends, and welcome to episode 676 of the Juicebox Podcast.

Today on the Juicebox Podcast, I don't know why I'm talking like this. Let me start over again. On this episode of The Juicebox Podcast, I'll be speaking with Jake leech. Jake is, you know from Dexcom. He's been on the show a bunch of times. And he's here today to talk about g7. It's a short episode, but it's full of good information. If you're looking forward to the Dexcom g7, you're going to like what comes next. While you're listening today, please remember that nothing you hear on the Juicebox Podcast should be considered advice, medical or otherwise, always consult a physician before making any changes to your healthcare plan, or becoming bold with insulin. If you are a US resident who has type one diabetes, or is the caregiver of someone with type one, your answers to simple questions are valuable. Go take the survey AT T one D exchange.org. Forward slash juice box in fewer than 10 minutes, you will help people living with type one diabetes while you're supporting the Juicebox Podcast.

This episode of The Juicebox Podcast is sponsored by us Med, get your diabetes supplies from us med find out more and get your free benefits check by going to us med.com forward slash juicebox. Or you can call I love reading the phone number. It brings me back to my childhood when I watched television, I was who my parents were the television. And then the ad was nevertheless ready. 888-721-1514 That's 88721514 Call now. That is how every ad when I was a kid ended? Was that the phone number that they said call now. Anyway, if you call that number, or you go to the link, you can get a free benefits check and get started with us, man. I'll tell you more about them later. I actually just switched over Arden's on the pods to us med.

Jake Leach 2:25
We're working on getting g7 approved, sorry about being late. It's not a stupid excuse. That's literally what I was on the phone talking about. That it's approved, don't take that as long as the record is more of like three questions. All

Scott Benner 2:42
right, hold on a second, I can't get my light to come on. So I'm going to be in the dark. But I'll still be see if I can throw a secondary light on. No worries. Let's see. Hey, how are you? Good, man. How you doing? I'm on okay. So is that really what you were doing? You weren't just like in the bathroom? And you couldn't get here on time? What was that? No,

Jake Leach 3:08
no, literally, I was I was on the phone with our team, we're, you know, back and forth with the FDA, they ask a question and you answer it, then they want some more clarification you answered. And I mean, it really comes down to there's just so much in these filings that they you know, they can't possibly read all 38,000 pages. So they just kind of pick areas that they want to spend some time with. So we ended up helping point them to the right places. And so it's very, it's really interactive. It's great. And very thorough, but it takes a little time.

Scott Benner 3:36
Yeah. Does the integration with algorithms change your submission? Or is that on the pump person side?

Jake Leach 3:42
That's on the pump side. Yes, the pump side, they basically once we get G seven approved as an IC GM, then they quickly do their submission. They've a little bit of validation work they have to do on their side to show that they have compatibility with the new G seven system. But it's all of this is based on the work that FDA has done to do the I CGM and the AI Controller it really facilitates quicker approvals. If if they wouldn't have done that, it almost likely wouldn't, you'd have to run a new study with every generation of technology instead of trying to make them more compatible. So it's pretty it was good forward thinking on the FDA has purposely set it up. So yeah, each of those pump companies will have a submission right after we achieve seven approved that they'll have to go through to get the g7 approved for use with their automated insulin delivery systems.

Scott Benner 4:31
Do you think that I'm going to ask you to speculate Do you think that's something they have ready to go and they're just waiting for you to get your Okay, so they can submit theirs? Or is it a process that like starts at day one when you

Jake Leach 4:40
know No, there are both both of them in tandem and insulet are already working on g7 integration. I've already seen prototypes working of their systems so they you know, they're not ready to like file it right away. They might be by the time we get to seven approval we'll see you know, because you know, probably a little More review time on D seven. So we'll see. Hopefully, I mean, they're moving as fast as they can. We're supporting them in every way to help them move as fast as possible. But there will be some time where people will stay on G six, if they're on those systems before they can move to G seven. What was I'm going to jump around a little bit here. Do you mind? No, I'm no problem, man.

Scott Benner 5:19
Good to see you got approval overseas already? Yeah,

Jake Leach 5:24
we got to see Mark last last month. And you know, we'd like to move fast. So we already moved into a limited launch. So g7 is in the hands of customers in the UK right now. That the recent attd show that just is wrapping up in Europe, they, we had a number of clinicians that have used the product as well as some of their customers. And they shared a little bit feedback, feedbacks been great. No surprises. Everyone loves the smaller size, easy use new app, the grace period, the 30 minutes start up, the more configurable alerts. For convenience, there's just there's a whole lot in g7. So pretty, everyone's pretty happy with it. We're happy with how it's going. We do these limited launches just to test, you know about the product, but also just our systems technical support, make sure we know how to support this, the last thing you'd want to do is go big and then have an issue that while it's fit, correctable it's kind of hard to correct when you're hurt. Yeah. At the scale we're at. So you want to get it going a little bit slower at first,

Scott Benner 6:23
was that the first time that that's happened that you've gotten something moving overseas before in the US on a new products?

Jake Leach 6:30
No, it's you know, there's been lots of different reasons over time where this has happened. I'll give you one example is g4 actually was approved first in Europe, with the Animus pump of all things right. So that was actually a previously approved version. So that was, you know, then we ended up redesigning some of the GE for for a product, he made it g4 Platinum, and then launched it. This one was just the case here is that the clinical trial that we had to run for the FDA is a little bit larger and takes longer than we the one that is required for the regulatory agencies in Europe. So we purposefully ran two separate trials, we wanted to get the product out as fast as we could. So we ran a trial for Europe. And we ran a separate trial for the US. And we submitted the European submission while we were still running the US trial.

Scott Benner 7:21
Okay. Can I flow through some questions real quick? I think they're going to be kind of kind of quick ones? No, of course. Excellent. I have these are from people who listened to the podcast who want to know what they want to know. I'll, I'll start with, they're wondering if the new form factor of G seven cuts down on compression lows. I've asked you guys this question in the past? And the answer has been We hope so. But I was wondering if you have any more data? Yeah, we don't, I don't have anything valid validated to say, you know, if

Jake Leach 7:51
you place the sensors in the exact same spot, and you lay on it in a, you know, statistical format, does it reduce compression, those, I don't have that, but what we have seen is that with the size of g7, it can be worn, you know, in slightly different locations on the particular the arm, where you can kind of move it around that because the sensor probes shorter, it's also more comfortable in the arm. So people have found like they can wear a little bit lower and there are a little bit higher. So we have seen people that they experienced professional have figured out how to move it around a bit so that they don't don't have it, but they still can happen on g7. But from a statistically significant perspective, I don't have an exact answer. Is it less, but it's certainly more comfortable to wear? Because it's so much thinner.

Scott Benner 8:36
Yeah. Hey, you just mentioned the sensor probe, does it go on in on a different angle than the G six?

Jake Leach 8:42
It does? Yeah, it goes straight in. It's a 90 degree angle versus the 45 degree angle. And what we were able to develop sensor technology within our electrodes that allow us to have a shorter sensor probe. So the depth is actually slightly shallower than G seven or G six. So G seven shallower than G six. And it's also less sensor probe under the skin because it's straight in versus that 45 degree angle.

Scott Benner 9:04
Oh, no kidding. So the G six is it? Am I ready? Test my memories at 13 millimeters? Yes, yes, exactly. I can't believe this is how long I've been doing this chicken. Bird right off the top of my head. What about the g7? Is it? Do you know the measurements? six millimeters? six millimeters? Oh, that's amazing. Oh, cool. Is the change in size going to impact the cost at all? I think what people are asking. Moreover, as do you see yourself as a competitor with libre or a different? Are you in a different space than they are?

Jake Leach 9:38
Well, actually, Scott, that is a very good question. So we're definitely looking at a portfolio of products. So in Europe, we've launched a new product called Dexcom one which is going to be in same the same markets as our G seven product as well. Usually six but we'll be replacing G six with G seven. The ideas There's certain in certain countries, people have access to GS six, but they may not. There's some people that don't have access to G six. So for example, right now, it's some countries categorize if you're at higher risk, meaning maybe a pediatric whose parents are taking care of their diabetes management or someone who's hypoglycemic and aware, they absolutely have to have alerts and alarms. Those folks have access to G six, there's a large population of people that don't have access to G six, they have access to other technologies. And so what we did was with Dexcom, one, we brought in the product, it's doesn't have all the same functionality as G six. It's a simpler product, but it still has alerts and alarms, it's still all based on the same accuracy, same hardware platform with a new mobile application, the whole purpose of that product is to help grow our business internationally and give more people access to Dexcom CGM. And so that product, you know, just over the past year, we've we've opened up over a million new people who have access to Dexcom that have never had it before around the globe. So that and then we're kind of just starting with that we've launched in a few countries with Dexcom. One, and we plan to launch in quite a few more. But, you know, getting back to that question around cost, you know, g7 is not intended to be more expensive, or at a higher out of pocket for people, it's, you know, part of people's cost of the product is have their insurance coverage. But you know, there's 30% of our customers don't pay anything. And you know, the other 30% pay quite a low copay, I think it's less than 30 $60 per month. So it's, you know, g7, one of the things about launching it is there's some coverage that we have to get for the product to ensure people can transition from G six to G seven, or get coverage for D seven. So there's some steps we take once we get FDA approval.

Scott Benner 11:51
So for people who are out of pocket, though, will there be an increase from cheese?

Jake Leach 11:55
I don't believe so. Yeah, I'm not. I mean, I'm not deep into the pricing discussions, but I don't expect it we don't have any expectation that we're increasing price for QBO. Customers,

Scott Benner 12:06
okay, great. When, eventually, one day when on the pod five and control, like you are compatible with G seven, and they're through FDA and everything, this is a big, I know this isn't really a question for you. But I got asked so many times, today, I'm going to bring it up anyway. If someone set up with GE six on one of those systems, and they move to G seven is it going to just be as simple as going into a setting and telling it I'm using the G seven now not the G six

Jake Leach 12:33
there, you know, each each, the architecture, these systems are a little bit unique, right? Each one is, you know, the Omni pod has the algorithm on on top of the disposable, you can look at control IQ, it's built in to the pump. And so you take control IQ for an example, when you want to upgrade to G seven, there'll be a firmware update that's required on the pump. Similar to my expectations be similar going from Basal IQ to control IQ, and they did the you could do the update is going to be something similar to that is what I would expect. And, you know, with Omnipod, it's likely a new firmware version on the pod, right that can communicate with G seven. So I think it's gonna be you know, the whole point is it's very easy for customers to do it. It's not like you have to get a whole new system. It just you know, it's about making these systems upgradeable. That's the whole point of trying to be able to keep up with the innovation that's going on in you know, sensors AI D they're all on slightly different timelines, but you want them to come together. So Right. That's why the FDA is approach with a CGM was such a good approach

Scott Benner 13:37
of let's see, oh, people want to know about overlaying session time. So we'll with g7, will there be a possibility of putting on a new one while you're still wearing an old one?

Jake Leach 13:47
There? There is completely you can do that if you want. With the 30 Minute startup time, though, it's it's not quite the same challenge that you're trying to solve for. Because right now, you know, I get feedback from customers that the two hours that they don't have the CGM data while it's doing its warm up at the initial beginning session is a terrible time because you know that the ID systems are not working or they're not getting that data, they're flying blind. So you do have a 30 minute startup with G seven, G seven starts the sensor session immediately upon insertion automatically you don't have to do anything so it just starts Okay. And you get into 30 minutes later I get data. Literally you get data Yeah, accurate, reliable data.

Scott Benner 14:35
US med is a place where you can get your diabetes supplies, they offer you white glove treatment. US med is a number of things. I'm gonna rattle them off for you right now ready, the number one distributor for FreeStyle Libre systems nationwide. They are the number one specialty distributor for Omnipod dash, the number one fastest growing tandem distributor nationwide, the number one rated distributor index com customer status faction surveys. How about that? They have served over 1 million people with diabetes since 1996. They always provide 90 days worth of supplies and they have fast and free shipping. That's right us med carries everything from insulin pumps and diabetes testing supplies to the latest and CGM, like FreeStyle Libre two, and the Dexcom G six. Here's a little personal information for you that you really have no business knowing, but I will tell you anyway, I just had Arden's prescription for Omni pod five, sent to us Med, they accept Medicare nationwide, and over 800 private insurers, you should check out us Med and find out why they have an A plus rating with the Better Business Bureau. How do you do this? Well, you can do it with a link us med.com forward slash juice box or by calling this special number just for Juicebox Podcast listeners. That number is 888721151 for us med wants you to get your diabetes supplies, they want you to have a better experience than the one you might be having now with whatever company is sending you your supplies, switch to us Smith. But also remind you to go to T one D exchange.org. Forward slash juice box and fill out the survey. And lastly, that the links to us med T one D exchange and all the sponsors are available in the podcast player that you're listening in right now. Like go in there. There's like shownotes, they're right in there, or they're available at juicebox podcast.com. Super important. When you click on the links, you're supporting the podcast if you love the podcast, if you love how much content there is, and that it's free for you. Supporting the sponsors and sharing the show with others are the two quickest way is to keeping it going.

Is there is there any kind of wonkiness in the first 24 hours like some people see what G six

Jake Leach 17:03
the all, you know, my experience with CGM technology over you know, last 20 years is that always the first day, and there's more a little more variability in that day at times some people experience it more than others, some people, you know, experience once in a while. And it really just comes from the form of kind of wound response from inserting a sensory of a brand new sensory insertion site. There's a whole lot that's actually going on from a physiology perspective. And so that does create variability in the first day. And so the performance is still really good. But yeah, you can have some of that, you know, signals that generally they run a little lower sometimes, you know, that give you a bit of a dip in the sensor signal. But still still accurate and reliable, but not, you know, not perfect. It's clearly the meds on the later days are better than the initial days.

Scott Benner 17:58
Things I think we know already were times 10 days.

Jake Leach 18:00
It's actually 10 and a half days. Okay, there's a there's a new feature called grace period. And

Scott Benner 18:07
we talked about that before. I have not spoken anything about it yet. No. So yes,

Jake Leach 18:11
we have this new new feature on G seven that was basically designed based on feedback from customers saying, you know, when the sensor stops showing data exactly 10 days after I insert it, it's not always the most convenient time to change my sensor. So sometimes I have to stop my sensor session earlier to replace the sensor, because you want to do what's convenient. So the the 10 and a half day we're on g7. The grace period, which is 12 hours is basically once you get to your 10 days from sensor insertion time, so let's say you did at four o'clock in the afternoon 10 days later at four o'clock in the afternoon and it's saying hey, we're going to time your sensor off we actually want you seven extend it we notify you saying hey, your sensors expired, but you have another 12 hours to find a time that's convenient for you to replace your sensor.

Scott Benner 18:56
Wow. Do you have anything that will make my daughter actually pay attention to that message when it pops up and says a little arm that'll come out of it and like knock around their house or something like that? I say change your sensor art and what happened? I don't know. It told me something earlier but I didn't read it. That was great. Thank you

Jake Leach 19:17
every time you go every Yeah, we're trying.

Scott Benner 19:21
I know you guys have been doing I know that you've been doing testing on adhesives because listeners of the podcast through T one D exchange have gotten opportunities to be in trials for but have you got any? Any results from that yet? Or people are asking a lot about adhesives. We have

Jake Leach 19:38
Yes. So a couple couple things on adhesive. So G seven has a new adhesive. It's different than G six. It looks similar, but it doesn't have some of the compounds that we've identified that can be irritants for some people. So the within the adhesive of G six we've through those tests that we were really happy that people were supporting those trials and participating in them, and wearing all the different types of patches, because it really did help us learn about some of the compounds that can cause irritation. They're not identified as irritants, but they ultimately can become them for certain people. So g7 doesn't have those in it. And actually, with G six, we've been working on a version of the patch that doesn't have those same compounds in it, a little bit of its proprietary between us and our patch supplier. But we basically are very focused on ensuring that we have as little irritation as possible, while still sensitive, having sensors last you know, that he here to the body, it's kind of like this little bit of a balancing act at work. But we've learned quite a bit over the last year and a half with those studies. So appreciate everyone participating in those that can and people will see it in the products, which is seven in particular, did it become more easy? Because the product is smaller? Does the adhesive not need to be as strong because it's not holding on as much weight? Or did that not? No, it was just it's just basically using some different types of adhesives and not including the same ingredients. And also some of the manufacturing processes we use are different with G seven that also helped enable using some different adhesives, they literally if you look at it, you can't tell the difference. But the g7 adhesive is, is strong. It's not less strong than G six. You're right, though it's quite a bit smaller, which is nice. Yeah. And then also with every g7, we supply the over patch for use if folks want to it's automatically placed in the box. And so you'd have to call for that separate

Scott Benner 21:39
burners, DME, durable medical, pharmacy, Medicare, how is that all going to be covered?

Jake Leach 21:48
So generally, for GCC, so you're basically asking me when we transition to g7? Yeah, well, there's a basic Yeah, the it's a bit of a, it's a bit of a process, the DME and Medicare usually moves a little faster than all of the pharmacy contracting. So you would expect that DME coverage would come quite quickly upon FDA approval, and then the pharmacy contracts will work their way over time. But we are working on programs to ensure that customers can get G seven as fast as they can. So more to come there. But it does, it does take a little bit of time to get the G seven into everybody's systems in the pharmacy and available for every all the patients that have G six today.

Scott Benner 22:29
Okay, well, G seven, show any improvement over sensor errors and not lasting 10 days for people.

Jake Leach 22:36
Yeah, it's, it's similar. It's similar in terms of g six. But what we have seen is that, and I know a lot of customers do wear G six in their arms. But we are seeing with G seven quite good sensor longevity when worn in the arm. And so if you look at the clinical trial results that we've published, we get better performance in the arm that we do the abdomen, the abdomen, still very good performance, but the arm is better. And so we we've we've kind of known that, or we thought that that was the case for quite a while, but we'd never run enough large clinical validation study work to really prove it. But with the g7 studies that we ran for approvals, they were quite large, you know, hundreds and hundreds of customers or patients subjects in the study, and both pediatrics and adults. And that we saw in both cases the arm performance was it was more accurate and lasted longer in the arm.

Scott Benner 23:30
Interesting. Are you expanding the approved places? Or is it still the same as before?

Jake Leach 23:34
No are no g7 Our intent is to get an arm indication to get definitely it'll be indicated for use in the arm.

Scott Benner 23:40
I often only wear scars on her hips. So I'll be interested, I wonder if the size change would maybe get her to move it to her arm. That'd be great.

Jake Leach 23:50
It's it's it is quite convenient. With the size and it's one of the things like it's kind of obvious, but when you actually experience a product, you You do understand how much smaller it is and basically forget you're wearing it is really quite different than my LG six experience. Okay, excellent.

Scott Benner 24:07
Smartphones at launch, are you adding any, are there going to be the same ones that people get for G six.

Jake Leach 24:12
So we so we're basically the way we approach smartphones is we're always working on whatever the latest available phones are. And so with Apple, you know, always takes us a little bit a little bit of time to get all of the validations and testing approved and you know, through the system. So you often get a little warning that says we're still in the middle of testing this GPU kit. Okay, and you can continue to use it. But we are still in the formal validation phase. So won't be any different with G seven Apple will we're working on the latest phones and iOS is there. Same with Android, right? The Samsung models are are the ones that we support the most number of phones, but we you know we are internally working on programs where we do want to support more handsets. We think about it as we go global right? We're During this global business in the US and outside the US and you know, there's a lot of different handsets out there. And so we're working on ways to be able to support more. And for us, it's really just about can we enhance our efficiency in the testing that we do to validate, we have to validate every single phone to ensure that the Bluetooth performance meets the requirements, because the alerts and alarms of our products are so important. And if the Bluetooth isn't reliable on that particular handset, which is not uncommon, then we really don't want customers using them. So that's why they end up not being supported. Yeah. A lot. A lot of people say, Well, we get support, tubular support anything, but it's actually interesting. And within each cell phone, there's some different hard functionality, in particular on the Bluetooth chips. And they're not all as reliable as we would want.

Scott Benner 25:46
Yeah, I guess Speaking of things that integrates with Apple Watch g7 to Apple Watch.

Jake Leach 25:53
So geez, yeah, so at launch, you'll have the same functionality as G six in the US launch with, with a secondary display of your information on on your watch, you can clear your alerts. So you basically you get the alert, you can acknowledge it on the watch. But the director, watch, we did build it into the hardware of G seven. So the wearable has the capability to do that functionality. And we're looking forward to some an upcoming release of a new watch OS that has a bunch of support in it that we need to help us make that feature actually happened.

Scott Benner 26:31
How about Garmin,

Jake Leach 26:32
Garmin will be the same as it is today, which is the functionality where if you have the Garmin Connect app, then you can, you know, basically put G seven data on your garmin watch, you just it's it'll be the exact same process. The beautiful thing about those cloud API's that we've launched with partners like Garmin is that which is G 60, G seven, it's a very simple update on our side. And then you may have to log back in, log out and log back into your account with that g7 credential. But really simple

Scott Benner 27:03
check, you have to go where do I have more time? Now you have a few more time? Yeah, I

Jake Leach 27:07
was late. You have more time.

Scott Benner 27:08
Excellent. Thank you. I was like, I'm not sure if I'm getting if we have to go or not. So I didn't want to I don't want to drag you along. So let's talk about that for half a second. Somebody asked me a question that I wasn't going to ask you. But based on what you were just talking about with Apple Watch, I'd like to understand this piece a little better. The question was, could you get me functionality with the apps where it calls me for a low at like sugar made has was which was the statement? And what made? What made me think I wouldn't ask the question is, in my mind, if you can't say that it's going to do it? Definitely, then you can't get it through the FDA. And so that's where functionality like that becomes less easy to try to put into place. Am I right about that?

Jake Leach 27:51
You are you are Scott, you know, the one of the most critical things our product does is the alerting in the FDA and our Dexcom as well view that is it's a really important aspect of the product. And so when it comes to safety, it is the thing that saves lives, when you get those low alerts. And so it, it is something that validation of those things takes, you really have to go through a lot of different use cases, edge cases, all kinds of stuff to make sure you have absolutely everything covered. And that's really been what you know, as we've worked on the director watch with on the Apple Watch platform, ensuring that every user gets reliable alerts, when that thing becomes your main receiver, your phone's not around, your receivers are on your pumps not around. So you're not getting an alert, unless it comes from that watch. And so being able to do that reliably has been something that Apple and Dexcom have worked together on to ensure that that can happen. And from my perspective, on the technology side, we're really close to being being able to introduce that functionality. But as you mentioned, the call feature, it's very similar in that it just has to happen. We do know our partner, sugar mate has that functionality. And trigger mate quickly connected up to our real time API once it's been available now and so there, they do have that. So it's not on our roadmap to add that. But you're right though about it gets pretty difficult to do some of those things what

Scott Benner 29:21
it scared you if I if you say hey, if this thing reaches a certain number, we're gonna send you a phone call. And I don't know it has to do with a cell network and the cell network was down. Then suddenly the alert you told me I was gonna get didn't come and there's nothing you can do about it. So you can't put yourself in that position to begin with.

Jake Leach 29:38
Yeah, yeah. And you probably will call us and it'll be a complaint that hey, it didn't work and we're gonna have to investigate it. And so yeah, it definitely is one of the things that when we when we're doing you know, we listen to customer feedback. A lot of the features in G seven are based on the great feedback that we've gotten from customers around g six, right. And so we we We're very thoughtful about which features we introduced and how we prioritize them. And you're bringing up one of the things that's can actually can add some complexity for sure. G seven is going to be approved for what ages? It's same as G. 602. And up to that's the intent.

Scott Benner 30:17
And let me just ask you about the apps little bit because I feel like we've been talking about these revamped apps for I'm gonna say forever. Maybe, so little things, you wouldn't you wouldn't tell me last time we talked, but are we gonna see rate of change on the new apps?

Jake Leach 30:33
So not not immediately. But it is definitely in the roadmap, because we've gotten a lot of feedback on that. And actually, after our last call, I dug in to see where in the feature priority list it was. So it's not in the initial release. But one of the things that we're doing different with G seven is we have a cadence, we call it our release trains. But we have a whole cadence of things planned for the next couple of years to bring significant value to customers through new versions of the app we've been in the past, you know, which is six, we didn't bring, you know, we did a number of enhancements to it. But they weren't as frequent as I want, as we want. And so what we're working on is, how do we bring more value faster, and it's really doing a lot of what, you know, the tech industry does, in our software team looks much, much different today than it did even a couple of years ago in terms of size, capability and breadth. So what I'm really excited about what we're going to be doing with our apps, as we continue to go forward,

Scott Benner 31:32
do you anticipate more frequent app updates than have been normal in the past?

Jake Leach 31:37
That's, that's the intent. That's what that's the expectation we've set for ourselves is that we're going to be developing features at a much faster cadence than we had in the past.

Scott Benner 31:47
Okay, so I'll hit you with these little things that seem like messages more than questions since the last one, like it might have helped in the past. One of them was overwhelmingly more Android phones, please, which we already talked about. People feel very passionate about the packaging being lesser every time and the ability to recycle things. A lot of people give feedback about that. And then there's a message for you here, which I'll save to the end. But this is the last question, which I think is hilarious as you're trying to get g7 through the FDA. What is GA going to be like?

Jake Leach 32:23
Well, we wouldn't be we wouldn't be Dexcom if we weren't already working on that. So yeah, absolutely, we are working on GA, it's a another kind of step in the wearable technology, making it you know, less than even, you know, more discrete. Manufacturing scale, right, that's become a very important part of how we design our sensors is we need to be able to manufacture you know, hundreds of millions of them. And so there's a bunch of that kind of technology that's going into g8 g7 is going to be a big focus for us, though, our plan is to roll it out as fast as we can across the globe and reach millions of customers with it. And so, yeah, GA is a program, we are running it, and we're excited about what's going on there. But you're not gonna get any secrets at me today.

Scott Benner 33:11
Well, then I'm still gonna ask my last question. Do you have any idea when this might happen?

Jake Leach 33:17
You say an FDA approval and g7 lunch? Yeah, my expectation is it happens this year. We've got you know, we're in that back and forth period with the FDA. Things are going great. We're really happy with how the good the interaction. And so you know, we're thinking sometime after Ada, likely So Ada is coming up here in June. And so, you know, our last earnings call we talked a little bit about, you know, our expectation is sometime after AD will get approval, and then we'll be launching but in a meaningful way this within this this year. It's not like we're launching on December 31. That's not our intent, right? Of course, regulatory timelines are always I've always Kevin CRC, you know, everybody asks us to predict when the FDA approves the product. And so it's, you know, we basically are saying our best estimate at this point, given what we know today is that it'll be some time after ADA but will allow a full launch at but this year, Jake,

Scott Benner 34:14
Kevin's more fun around these questions. And you are, I just want you

Jake Leach 34:17
to know he can be

Scott Benner 34:20
and there's a number of messages from here from people who just wanted me to say thank you for the technology. So I won't I can't read them all to you. But a lot of heartfelt thanks came through as well.

Jake Leach 34:31
Very, very much appreciate all the folks that that use our technology every day to you know, help them manage diabetes.

Scott Benner 34:38
Yeah, no, thank you for taking the time to do this. I appreciate it. Cool. Thanks, guys. Take care Jake. Jake, you think we'll be doing this

I bet you want to know what I asked Jake when I shut off the recording and what he answered, but I guess I'm telling you thank you so much to Jake leech for coming on the show and talking today about Dexcom g7. And thank you to us med for sponsoring this episode of The Juicebox Podcast head over now to us med.com forward slash juice box or call 888-721-1514 Get your free benefits check and get started today with us med. Getting your diabetes supplies should not be difficult, and with us med it won't be

if you're new to the Juicebox Podcast, hit subscribe in your podcast app or any audio app that you're listening in, for instance, audible Spotify, Apple podcasts, etc. etc, etc. Hit subscribe or follow follow and subscribe. Get the next episode right there on your phone. If you're looking for support online, the Juicebox Podcast has a Facebook page it is a private page with nearly 25,000 people in it. They all use insulin or love someone who uses insulin. And they're having vibrant and valuable conversations all day long that you may enjoy. You could get involved in them or just kind of look around and see how people handle things. It's actually very helpful. And a great way to learn about type one diabetes management and the use of insulin in general. So I'm saying type two as well. You hear me? Thank you so much for listening. I'll be back very soon with another episode of The Juicebox Podcast.